EsoCap reports positive topline results from ACESO Phase II trial investigating ESO-101 in eosinophilic esophagitis
05 déc. 2023 03h00 HE
|
EsoCap AG
ESO-101, EsoCap's lead product candidate, consists of a capsule with a rolled-up, thin mucoadhesive film with the anti-inflammatory corticosteroid, mometasone furoateEsoCap's novel targeted delivery...
EsoCap completes patient recruitment in ACESO Phase II trial in eosinophilic esophagitis
05 sept. 2023 03h30 HE
|
EsoCap AG
EsoCap's novel targeted delivery platform is designed to increase mucosal contact time and drug deposition in the esophagus ESO-101, EsoCap's lead product candidate, consists of a capsule with a...
EsoCap holds a multidisciplinary advisory board meeting on Barrett’s esophagus
14 juin 2022 03h32 HE
|
EsoCap AG
EsoCap AG organized a multidisciplinary scientific advisory board meeting with eight international experts in Barrett’s esophagus (BE) in ZurichEsoCap’s technology for the topical treatment of...
EsoCap supports first European EoE Day of the European Society of Eosinophilic Oesophagitis on May 22, 2022
20 mai 2022 05h00 HE
|
EsoCap AG
Patients with eosinophilic esophagitis (EoE) suffer from severe symptoms including swallowing disorders, food impaction, vomiting, and heartburnEsoCap is currently conducting a randomized,...
EsoCap and Upadia sign exclusive licensing agreement combining EsoCap technology with Upadia antibodies for the treatment of Barrett’s esophagus
10 janv. 2022 05h32 HE
|
EsoCap AG
Licensing deal grants EsoCap exclusive access to Upadia’s monoclonal antibodies for a local therapy for Barrett’s esophagusBarrett’s esophagus, a disease of the esophagus with high unmet medical need,...
EsoCap secures new funding
18 nov. 2021 08h30 HE
|
EsoCap AG
EsoCap successfully closes a private financing round, with investments from existing and new investorsThe new funding was facilitated by EsoCap benefitting from a unique programme implemented by the...
EsoCap announces first patient enrolled in Phase II eosinophilic esophagitis trial
26 oct. 2021 03h00 HE
|
EsoCap AG
Randomized, placebo-controlled, double-blind Phase II trial to treat 42 patients ongoing in four European countries with ESO-101ESO-101, EsoCap’s lead product candidate, consists of a capsule with a...
EsoCap – unique targeted application platform to treat the upper gastrointestinal tract
09 sept. 2021 03h00 HE
|
EsoCap AG
EsoCap’s targeted application technology drastically increases mucosal contact time and enables effective local treatment of various esophageal diseases for the first timeProof of principle in human...